BCIQ Profiles

Company Profile ReportTarget Profile Report
0907 Quick Takes
BioCentury & Getty Images

Product Development

Sept. 7 Quick Takes: Parsing the BioMarin gene therapy hold

Spark, NeuExcell teaming for Huntington’s therapy, plus venture rounds for Emulate, Owlstone, EnteroBiotix, Locate and more 

Sep 8, 2021 | 12:40 AM GMT

Though evidence is lacking that tumorigenic potential of AAV vectors in mice translates to humans, FDA placed a clinical hold on the Phase I/II Phearless trial of AAV5 gene therapy BMN 307 from BioMarin

Read the full 699 word article

How to gain access

Continue reading with a
two-week free trial.